Navidea Biopharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 08 2020 - 4:05PM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB)
(“Navidea” or the “Company”), a company focused on the development
of precision immunodiagnostic agents and immunotherapeutics, today
announced that Mr. Jed Latkin, Chief Executive Officer, will
present at the H.C. Wainwright 22nd Annual Global Investment
Conference. The virtual conference will be held on September 14-16,
2020. Mr. Latkin will present on Wednesday, September 16 at 10:30
a.m. EST.
Details of Navidea’s presentation are below. For those who wish
to listen to the live webcast, please use the following link:
https://wsw.com/webcast/hcw7/navb/1597167. The webcast will be
archived on Navidea’s investor relations website,
https://ir.navidea.com/news-events for 90 days following the live
presentation.
Event: H.C. Wainwright 22nd Annual Global Investment
Conference Date: Wednesday, September 16, 2020 Time:
10:30 - 10:50 a.m. EDT Location: Virtual Conference
Presentation Webcast Link:
https://wsw.com/webcast/hcw7/navb/1597167
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept™ platform to enhance patient care by identifying the sites
and pathways of disease and enable better diagnostic accuracy,
clinical decision-making, and targeted treatment. Navidea’s
Manocept platform is predicated on the ability to specifically
target the CD206 mannose receptor expressed on activated
macrophages. The Manocept platform serves as the molecular backbone
of Tc99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. Navidea’s strategy
is to deliver superior growth and shareholder return by bringing to
market novel products and advancing the Company’s pipeline through
global partnering and commercialization efforts.
For more information, please visit www.navidea.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. We have based these forward-looking statements largely on
our current expectations and projections about future events and
financial trends affecting the financial condition of our business.
Forward-looking statements include our expectations regarding
Navidea’s ability to enter into the ELDA on terms acceptable to
Navidea, if at all, potential benefits to Navidea under the ELDA,
Jubilant’s ability to act as an effective commercial and
distribution partner, and Jubilant’s expected expansion into the
radio-diagnostics market. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions,
including, among other things: our ability to negotiate and enter
into the ELDA on acceptable terms, if at all; Jubilant’s ability to
act as a successful commercial distribution partner; our history of
operating losses and uncertainty of future profitability; the final
outcome of any pending litigation; our ability to successfully
complete research and further development of our drug candidates;
the timing, cost and uncertainty of obtaining regulatory approvals
of our drug candidates; our ability to successfully commercialize
our drug candidates; dependence on royalties and grant revenue; our
ability to implement our growth strategy; anticipated trends in our
business; our limited product line and distribution channels;
advances in technologies and development of new competitive
products; our ability to comply with the NYSE American continued
listing standards; our ability to maintain effective internal
control over financial reporting; the impact of the current
coronavirus pandemic; and other risk factors detailed in our most
recent Annual Report on Form 10-K and other SEC filings. You are
urged to carefully review and consider the disclosures found in our
SEC filings, which are available at http://www.sec.gov or at
http://ir.navidea.com.
Investors are urged to consider statements that include the
words “will,” “may,” “could,” “should,” “plan,” “continue,”
“designed,” “goal,” “forecast,” “future,” “believe,” “intend,”
“expect,” “anticipate,” “estimate,” “project,” and similar
expressions, as well as the negatives of those words or other
comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any
forward-looking statements, any of which could turn out to be
incorrect. We undertake no obligation to update publicly or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise after the date of this
report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report
may not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.
References and links to websites have been provided as a
convenience, and the information contained on such websites is not
incorporated by reference into this press release. Navidea is not
responsible for the contents of third-party websites.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200908005806/en/
Navidea Biopharmaceuticals, Inc. Jed Latkin, CEO 614-973-7490
jlatkin@navidea.com
Joel Kaufman Head of Strategy and Business Development
614-822-2372 jkaufman@navidea.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024